D-0557-2023 Class II Terminated

Recalled by PD-Rx Pharmaceuticals, Inc. — Oklahoma City, OK

FDA drug recall D-0557-2023 was initiated by PD-Rx Pharmaceuticals, Inc. on Apr 6, 2023 and is designated Class II. Reason for recall: CGMP deviations. The recall status is terminated (terminated Apr 30, 2024). Affected quantity: 352 bottles.

Recall details

Product Type
Drugs
Report Date
May 10, 2023
Initiation Date
Apr 6, 2023
Termination Date
Apr 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
352 bottles

Product description

Montelukast Sodium USP, 10 mg, 30 count-bottles, Rx only, Intas Pharm, Limited Ahmedabad 380 054 India Pkg By: PD-Rx Pharmaceuticals Incorporated Oklahoma City, OK 73127, NDC 43063-0762-30

Reason for recall

CGMP deviations.

Distribution pattern

Nationwide in the US.

Code information

Lots: L22C80, I22D93, K21C72 Exp. 11/30/23; A23A90, B23A09 Exp. 07/31/24; K22C33 Exp. 05/31/24; G22E88, G22F66, I22E27, C22B27, D22B94, E22C71 Exp. 02/28/24; I21E36 Exp. 09/30/23

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0557-2023
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0557-2023. Report a data issue: hello@regdatalab.com.